1
Jochen G Salfeld, Deborah J Allen, Hendricus R J M Hoogenboom, Zehra Kaymakcalan, Boris Labkovsky, John A Mankovich, Brian T McGuinness, Andrew J Roberts, Paul Sakorafas, David Schoenhaut, Tristan J Vaughan, Michael White, Alison J Wilton: Human antibodies that bind human TNF.alpha.. BASF Aktiengesellschaft, Catherine J Kara, Elizabeth A Hanley Esq, Lahive & Cockfield, July 18, 2000: US06090382 (281 worldwide citation)

Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor .alpha. (hTNF.alpha.) are disclosed. These antibodies have high affinity for hTNF.alpha. (e.g., K.sub.d =10.sup.-8 M or less), a slow off rate for hTNF.alpha. dissociation (e.g., K.sub.of ...


2

3

4
Jochen G Salfeld, Deborah J Allen, Hendricus R J M Hoogenboom, Zehra Kaymakcalan, Boris Labkovsky, John A Mankovich, Brian T McGuinness, Andrew J Roberts, Paul Sakorafas, David Schoenhaut, Tristan J Vaughan, Michael White, Alison J Wilton: Human antibodies that bind human TNFα. Abbott Biotechnology, Elizabeth A Hanley, Cristin E Howley, Lahive & Cockfield, May 29, 2007: US07223394 (126 worldwide citation)

Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor a (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTN ...


5
Jochen G Salfeld, Deborah J Allen, Zehra Kaymakcalan, Boris Labkovsky, John A Mankovich, Brian T McGuinness, Andrew J Roberts, Paul Sakorafas, Hendricus R J M Hoogenboom, David Schoenhaut, Tristan J Vaughan, Michael White, Alison J Wilton: Methods for treating rheumatoid arthritis using human antibodies that bind human TNFα. Abbott Biotechnology, McCarter & English, Elizabeth A Hanley Esq, Cristin Howley Cowles, June 2, 2009: US07541031 (114 worldwide citation)

Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTN ...


6
Jochen G Salfeld, Deborah J Allen, Hendricus R J M Hoogenboom, Zehra Kaymakcalan, Boris Labkovsky, John A Mankovich, Brian T McGuinness, Andrew J Roberts, Paul Sakorafas, David Schoenhaut, Tristan J Vaughan, Michael White, Alison J Wilton: Human antibodies that bind human TNFα. Abbott Biotechnology, McCarter & English, Elizabeth A Hanley Esq, Cristin Howley Cowles, September 15, 2009: US07588761 (113 worldwide citation)

Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTN ...


7
Jochen G Salfeld, Deborah J Allen, Hendricus R J M Hoogenboom, Zehra Kaymakcalan, Boris Labkovsky, John A Mankovich, Brian T McGuinness, Andrew J Roberts, Paul Sakorafas, David Schoenhaut, Tristan J Vaughan, Michael White, Alison J Wilton: Human antibodies that bind human TNFα. Abbott Biotechnology, McCarter & English, Elizabeth A Hanley Esq, Cristin H Cowles, June 12, 2012: US08197813 (56 worldwide citation)

Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTN ...


8
Jochen G Salfeld, Deborah J Allen, Hendricus R J M Hoogenboom, Zehra Kaymakcalan, Boris Labkovsky, John A Mankovich, Brian T McGuinness, Andrew J Roberts, Paul Sakorafas, David Schoenhaut, Tristan J Vaughan, Michael White, Alison J Wilton: Human antibodies that bind human TNFα. Abbott Biotechnology, McCarter & English, Cristin H Cowles, February 12, 2013: US08372401 (55 worldwide citation)

Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTN ...


9
Jochen G Salfeld, John A Mankovich, Deborah J Allen, Hendricus R J M Hoogenboom, Boris Labkovsky, Brian T McGuinness, Paul Sakorafas, Michael White, Alison J Wilton, Zehra Kaymakcalan, Andrew J Roberts, David Schoenhaut, Tristan J Vaughan: Human antibodies that bind human TNFα and methods of using same. Abbott Biotechnology, McCarter & English, Cristin H Cowles, April 9, 2013: US08414894 (55 worldwide citation)

Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTN ...


10
Jochen G Salfeld, Deborah J Allen, Zehra Kaymakcalan, Boris Labkovsky, John A Mankovich, Brian T McGuinness, Andrew J Roberts, Paul Sakorafas, Hendricus R J M Hoogenboom, David Schoenhaut, Tristan J Vaughan, Michael White, Alison J Wilton: Methods of treating disorders using human antibodies that bind human TNFα. Abbott Biotechnology, McCarter & English, Cristin H Cowles, February 12, 2013: US08372400 (52 worldwide citation)

Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTN ...